Figures captions
Figure 1 PRISMA flow diagram of the review selection process
Figure 2 Forest plot depicting pooled estimates for the association between mortality and renin-angiotensin system drugs use
Figure 3 Forest plot depicting pooled estimates for the association between death/Intensive Care Unit (as a composite outcome) and renin-angiotensin system drugs use
Figure 4 Forest plot depicting pooled estimates for the association between severe COVID-19 infection and renin-angiotensin system drugs use
Figure 5 Forest plot depicting pooled estimates for the association between hospitalisation and renin-angiotensin system drugs use
Figure 6 Forest plot depicting pooled estimates for the association between developing Intensive Care Unit admission and renin-angiotensin system drugs use
Figure 7 Forest plot depicting pooled estimates for the association between between risk of acquiring COVID-19 infection and renin-angiotensin system drugs use
Figure 8 Forest plot depicting pooled estimate for the association between use of mechanical ventilator and renin-angiotensin system drugs use
Figure 9 Forest plot depicting pooled estimates for the association between risk of severe acute respiratory syndrome (SARS)and renin-angiotensin system drugs use
Figure 10 Forest plot depicting pooled estimates for the association between severe pneumonia and renin-angiotensin system drugs use